TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07200193: A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults With Chronic Hepatitis B

Sponsor: nChroma Bio · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 66 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,648,540

Rescue Site Savings

+$2,399,040

Unlock Full NCT07200193 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07200193 Rescue Dossier →